Group 1 - Morgan Stanley's Chief U.S. Equity Strategist Michael Wilson suggests that nominal GDP and earnings growth may support stock valuations due to rising inflation [1] - Since the new economic cycle began in April, the expansion of market P/E ratios has been driven by three factors: the start of a new cycle, expectations of future earnings recovery, and the support of a high inflation environment for stock risk premiums [1] - The current S&P 500 index to gold ratio is nearly 70% lower than its peak 25 years ago, indicating that stock prices are significantly lower than during the 1999-2000 period [1] Group 2 - Compared to the late 1990s, the current free cash flow yield of S&P 500 large-cap stocks is significantly higher, and the adjusted P/E ratio is about 40% lower than that time [2] - Wilson believes that the core competitiveness of the market today is stronger, with better free cash flow generation, higher operational efficiency, and solid profitability, indicating that the current market quality surpasses that of the internet bubble era [2] - Wilson predicts that April 2024 will mark the low point of the rolling recession that began in 2022, signaling the official start of a new cycle [2] Group 3 - Historical experience shows that the biotechnology sector performs strongly during Fed rate-cutting cycles, benefiting from declining back-end yields [3] - Recent positive signals in the biotechnology sector include the strongest weekly performance since 2022, driven by policies from the Trump administration and Pfizer regarding drug pricing [3] - The healthcare sector's relative valuation remains in the bottom 5% of its historical range over the past 30 years, indicating a high likelihood of outperforming the market [3]